Education
About Us
Working with TipRanks
Follow Us
Immunotech Biopharm Ltd (HK:6978)
:6978
RESEARCH TOOLSreports
6978 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$1.50 - HK$6.15
Previous CloseN/A
Volume50.00K
Average Volume (3M)542.70K
Market Cap
HK$2.04B
Enterprise ValueHK$1.93B
Total Cash (Recent Filing)HK$57.49M
Total Debt (Recent Filing)¥116.46M
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Aug 22, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding514,584,000
10 Day Avg. Volume744,700
30 Day Avg. Volume542,700
Financial Highlights & Ratios
PEG Ratio-298.68
Price to Book (P/B)-139.96
Price to Sales (P/S)0.00
P/FCF Ratio-18.77K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Immunotech Biopharm Ltd News
PremiumCompany Announcements
Immunotech Biopharm Ltd Strengthens Board with New Appointments
PremiumCompany Announcements
Immunotech Biopharm Ltd Announces Board Composition
PremiumCompany Announcements
Immunotech Biopharm Ltd Sets Terms for Nomination CommitteePremiumCompany Announcements
Immunotech Biopharm Ltd Announces Board Composition and Committee Roles
PremiumCompany Announcements
Immunotech Biopharm Announces Executive Resignation Amid Governance Dispute
PremiumCompany Announcements
Leadership Changes at Immunotech Biopharm Ltd Amid Governance DisputePremiumCompany Announcements
Immunotech Biopharm Ltd Secures Unanimous Shareholder Support at AGM
PremiumCompany Announcements
Immunotech Biopharm Ltd Announces 2025 AGM and Key Resolutions6978 FAQ
What was Immunotech Biopharm Ltd’s price range in the past 12 months?
Immunotech Biopharm Ltd lowest stock price was HK$1.50 and its highest was HK$6.15 in the past 12 months.
What is Immunotech Biopharm Ltd’s market cap?
Immunotech Biopharm Ltd’s market cap is HK$2.04B.
When is Immunotech Biopharm Ltd’s upcoming earnings report date?
Immunotech Biopharm Ltd’s upcoming earnings report date is Aug 22, 2025 which is in 35 days.
How were Immunotech Biopharm Ltd’s earnings last quarter?
Currently, no data Available
Is Immunotech Biopharm Ltd overvalued?
According to Wall Street analysts Immunotech Biopharm Ltd’s price is currently Overvalued.
Does Immunotech Biopharm Ltd pay dividends?
Immunotech Biopharm Ltd does not currently pay dividends.
What is Immunotech Biopharm Ltd’s EPS estimate?
Immunotech Biopharm Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunotech Biopharm Ltd have?
Immunotech Biopharm Ltd has 514,584,000 shares outstanding.
What happened to Immunotech Biopharm Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Immunotech Biopharm Ltd?
Currently, no hedge funds are holding shares in HK:6978
Immunotech Biopharm Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.78%
12-Months-Change
Fundamentals
Return on Equity
-228.99%
Trailing 12-Months
Asset Growth
-35.58%
Trailing 12-Months
Company Description
Immunotech Biopharm Ltd
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. In addition, it develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; and TCR-T cell series products to treat solid tumors. The company was founded in 2006 and is headquartered in Beijing, the People's Republic of China.
Technical Analysis
TOT BIOPHARM International Co. Ltd.
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
―
SinoMab Bioscience Ltd.
―
Zhaoke Ophthalmology Ltd.
―